MX2022003316A - Composiciones y métodos relacionados con constructos de fc-dominio de unión al antígeno diseñados por ingeniería dirigidos a cd38. - Google Patents

Composiciones y métodos relacionados con constructos de fc-dominio de unión al antígeno diseñados por ingeniería dirigidos a cd38.

Info

Publication number
MX2022003316A
MX2022003316A MX2022003316A MX2022003316A MX2022003316A MX 2022003316 A MX2022003316 A MX 2022003316A MX 2022003316 A MX2022003316 A MX 2022003316A MX 2022003316 A MX2022003316 A MX 2022003316A MX 2022003316 A MX2022003316 A MX 2022003316A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding domain
engineered
compositions
methods related
Prior art date
Application number
MX2022003316A
Other languages
English (en)
Inventor
Daniel Ortiz
Amit Choudhury
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MX2022003316A publication Critical patent/MX2022003316A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen constructos de Fc-dominio de unión al antígeno que tienen un dominio de unión a CD38 y dos o más dominios Fc, así como métodos para usar tales constructos. También se describen polipéptidos que forman tales constructos. Los monómeros de dominio Fc que se incluyen en los constructos pueden incluir sustituciones de aminoácidos que promueven la homodimerización o heterodimerización.
MX2022003316A 2019-09-18 2020-09-18 Composiciones y métodos relacionados con constructos de fc-dominio de unión al antígeno diseñados por ingeniería dirigidos a cd38. MX2022003316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962902380P 2019-09-18 2019-09-18
PCT/US2020/051663 WO2021055876A1 (en) 2019-09-18 2020-09-18 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38

Publications (1)

Publication Number Publication Date
MX2022003316A true MX2022003316A (es) 2022-07-11

Family

ID=74884204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003316A MX2022003316A (es) 2019-09-18 2020-09-18 Composiciones y métodos relacionados con constructos de fc-dominio de unión al antígeno diseñados por ingeniería dirigidos a cd38.

Country Status (10)

Country Link
EP (1) EP4031166A1 (es)
JP (1) JP2022548925A (es)
KR (1) KR20220119362A (es)
CN (1) CN114786713A (es)
AU (1) AU2020351234A1 (es)
BR (1) BR112022005036A2 (es)
CA (1) CA3155187A1 (es)
IL (1) IL291465A (es)
MX (1) MX2022003316A (es)
WO (1) WO2021055876A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56677B1 (sr) * 2005-10-12 2018-03-30 Morphosys Ag Proizvodnja i karakterizacija potpuno humanih terapeutskih antitela dobijenih hucal gold tehnologijom, specifičnih za humani cd38
CN110317272A (zh) * 2008-10-14 2019-10-11 霍夫曼-拉罗奇有限公司 免疫球蛋白变体及其用途
DK3105317T3 (en) * 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
WO2015197582A1 (en) * 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
US20200040084A1 (en) * 2017-01-06 2020-02-06 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs

Also Published As

Publication number Publication date
JP2022548925A (ja) 2022-11-22
KR20220119362A (ko) 2022-08-29
IL291465A (en) 2022-05-01
EP4031166A1 (en) 2022-07-27
BR112022005036A2 (pt) 2022-07-05
AU2020351234A1 (en) 2022-04-28
CA3155187A1 (en) 2021-03-25
WO2021055876A1 (en) 2021-03-25
CN114786713A (zh) 2022-07-22

Similar Documents

Publication Publication Date Title
MX2021000307A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.
PH12019550147A1 (en) Engineered transferrin receptor binding polypeptides
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
MX2018002226A (es) Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo.
NZ590668A (en) TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
NZ726448A (en) Improved immunoglobulin variable domains
TN2010000169A1 (en) Molecules and methods for modulating complement component
MX2023005201A (es) Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
WO2018169922A3 (en) Chimeric antigen receptors for melanoma and uses thereof
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
MX2021000290A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4.
MX2021000306A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4.
MX2021000287A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2021000280A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2022003316A (es) Composiciones y métodos relacionados con constructos de fc-dominio de unión al antígeno diseñados por ingeniería dirigidos a cd38.
MX2023010916A (es) Composiciones de proteinas de fusion quimericas modificadas por ingenieria y metodos de uso de las mismas.
MX2021011609A (es) Moduladores de interacciones de proteinas de superficie celular y metodos y composiciones relacionados con estos.
MX2021000281A (es) Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1.
MX2021000288A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2022001882A (es) Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
MX2021000305A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
AU2018278809A1 (en) Recombinant ROBO2 proteins, compositions, methods and uses thereof
WO2024064366A3 (en) Engineered chimeric fusion protein compositions and methods of use thereof